Genocea Biosciences Ownership

GNCADelisted Stock  USD 0.0002  0.0001  100.00%   
Genocea Biosciences has a total of 58.78 Million outstanding shares. Genocea Biosciences retains 6.22 (percent) of its outstanding shares held by insiders and 1.25 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Genocea Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Genocea Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Genocea Stock Ownership Analysis

The company has price-to-book (P/B) ratio of 0.01. Some equities with similar Price to Book (P/B) outperform the market in the long run. Genocea Biosciences recorded a loss per share of 0.53. The entity last dividend was issued on the 22nd of May 2019. The firm had 1:8 split on the 22nd of May 2019. Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Genocea Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 74 people. To learn more about Genocea Biosciences call William MBA at 617 876 8191 or check out https://www.genocea.com.

Genocea Biosciences Outstanding Bonds

Genocea Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genocea Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genocea bonds can be classified according to their maturity, which is the date when Genocea Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Genocea Stock

If you are still planning to invest in Genocea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genocea Biosciences' history and understand the potential risks before investing.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Transaction History
View history of all your transactions and understand their impact on performance
CEOs Directory
Screen CEOs from public companies around the world
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum